Overview

An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection

Status:
Completed

Trial end date:
2007-10-01

Target enrollment:

Participant gender:

Summary

This is an extension study of HCV-05-002. The objective of this study is to evaluate the safety and efficacy of celgosivir plus peginterferon alfa-2b, with or without ribavirin, for an additional 36 weeks in patients with chronic hepatitis C genotype 1 infection.

Phase:

Phase 2

Details

Lead Sponsor:

BioWest Therapeutics Inc

Treatments:

Interferon-alpha
Peginterferon alfa-2b
Ribavirin